Progestagens use before menopause and breast cancer risk according to histology and hormone receptors

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 10, 2008, Pages 2723-2728

  Fabre, Alban ^a   Fournier, Agnès ^a   Mesrine, Sylvie ^a   Gompe, Anne ^b   Desreux, Joëlle ^c   Berrino, Franco ^d   Boutron Ruault, Marie Christine ^a   Romieu, Isabelle ^e   Clavel Chapelon, Françoise ^a,f  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c Centre Hospitalier Regional de La Citadelle   (Belgium)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GESTAGEN; LOW DOSE ORAL CONTRACEPTIVE; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER RISK; CONTROLLED STUDY; FEMALE; FRANCE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INVASIVE CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SIDE EFFECT;

EID: 54249091768     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0056     Document Type: Article

References (33)

1. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76:27-36.
2. Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of agespecific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:1128-35.
3. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiologyand outcome. Breast Cancer Res Treat 2005;90:127-37.
4. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.
5. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005;92:2049-58.
6. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11.
7. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65.
8. Fabre A, Fournier A, Mesrine S, et al. Oral progestagens before menopause and breast cancer risk. Br J Cancer 2007;96:841-4.
9. Lowy I, Weisz G. French hormones: progestins and therapeutic variation in France. Soc Sci Med 2005;60:2609-22.
10. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk byhistological type: a cohort study and meta-analysis. Lancet Oncol 2006;7:910-8.
11. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007;26:2389-430.
12. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999;281:2091-7.
13. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88:2570-7.
14. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002;95:2455-64.
15. Newcomer LM, Newcomb PA, Trentham-Dietz A, Longnecker MP, Greenberg ER. Oral contraceptive use and risk of breast cancer by histologic type. Int J Cancer 2003;106:961-4.
16. Stalsberg H, Thomas DB, Noonan EA. Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1989;44:399-409.
17. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 2002;4:197-201.
18. Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tuchler H. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg 1993;218:13-21.
19. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 2003;21:4314-21.
20. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63.
21. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004;101:1490-500.
22. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-68.
23. Britton JA, Gammon MD, Schoenberg JB, et al. Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age. Am J Epidemiol 2002;156:507-16.
24. Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res 2006;8:R39.
25. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000;151:703-14.
26. Botella J, Duranti E, Duc I, Cognet AM, Delansorne R, Paris J. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J Steroid Biochem Mol Biol 1994;50:41-7.
27. Wei LL, Krett NL, Francis MD, et al. Multiple human progesterone receptor messenger ribonucleic acids and their autoregulation by progestin agonists and antagonists in breast cancer cells. Mol Endocrinol 1988;2:62-72.
28. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003;17:575-88.
29. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998;16:3115-20.
30. Pappo I, Meirshon I, Karni T, et al. The characteristics of malignant breast tumors in hormone replacement therapy users versus nonusers. Ann Surg Oncol 2004;11:52-8.
31. Biglia N, Sgro L, Defabiani E, et al. The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol 2005;31:467-72.
32. Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J. Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 2007;120:2202-7.
33. Lange CA, Richer JK, Shen T, Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 1998;273:31308-16.